e-Therapeutics plc Director/PDMR Shareholding (5013K)
January 04 2021 - 10:31AM
UK Regulatory
TIDMETX
RNS Number : 5013K
e-Therapeutics plc
04 January 2021
E-THERAPEUTICS PLC
("e-therapeutics" or the "Company")
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY
PERSONS
DISCHARGING MANAGERIAL RESPONSIBILITIES AND ISSUE OF EQUITY
Oxford, UK, 4 January 2021 - e-therapeutics plc (AIM: ETX), the
drug discovery company, announces that o n 4 January 2021 Professor
Trevor Jones (Non-Executive Director) subscribed for a total of
33,417 new ordinary shares of 0.1p each in the Company (the "New
Ordinary Shares") a t a price of 16.46 pence per share. The
subscription monies paid for the New Ordinary Shares represent 50%
of Professor Jones' Non-Executive Director fees net of tax paid
during the period from 1 July 2020 to 31 December 2020 in
accordance with the agreement entered into with Professor Jones,
previously announced o n 5 October 2016, by which Professor Jones
agreed, with effect from 1 October 2016, to invest 50% of his
annual Non-Executive Director fees net of tax in new
e-therapeutics' ordinary shares. Such new shares are issued to
Professor Jones on the first business day after 31 December and 30
June in each year. The subscription price to be paid is the average
of the closing mid-market price for the five business days prior to
the date of issue.
Following Admission, Professor Jones will be interested in a
total of 1,031,955 ordinary shares of 0.1p in the Company,
representing approximately 0.25% of the Company's issued share
capital.
Application has been made to AIM for the admission of the New
Ordinary Shares to trading on AIM ("Admission") and Admission is
expected to occur on 11 January 2021. The New Ordinary Shares will
rank pari passu in all respects with the Company's existing
ordinary shares in issue.
Following Admission, the total number of ordinary shares in the
Company with voting rights in issue will be 420,773,546. This
figure may be used by shareholders as the denominator for the
calculations by which they will determine if they are required to
notify their interest in, or a change to their interest in, the
Company under the Financial Conduct Authority's Disclosure and
Transparency Rules.
The notification below, made in accordance with the requirements
of the EU Market Abuse Regulation, provides further details:
1 Details of the person discharging managerial responsibilities/person
closely associated
a) Name Trevor Jones
-------------------------- -------------------------------------------
2 Reason for the notification
-----------------------------------------------------------------------
a) Position/status Non-Executive Director
-------------------------- -------------------------------------------
b) Initial notification/ Initial notification
Amendment
-------------------------- -------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-----------------------------------------------------------------------
a) Name e-therapeutics plc
-------------------------- -------------------------------------------
b) LEI 21380049RHSSJXWKYT18
-------------------------- -------------------------------------------
4 Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii)
each date; and (iv) each place where transactions have been
conducted
-----------------------------------------------------------------------
a) Description of the Ordinary Shares of 0.1 pence
financial instrument,
type of instrument ISIN: GB00B2823H99
Identification code
-------------------------- -------------------------------------------
b) Nature of the transaction Purchase of shares
-------------------------- -------------------------------------------
c) Price(s) and volume(s) 33,417 ordinary shares at a price of 16.46
pence per share
-------------------------- -------------------------------------------
d) Aggregated information 33,417 ordinary shares
- Aggregated volume 16.46 pence per share
- Price Aggregated value: GBP5,500.60
-------------------------- -------------------------------------------
e) Date of the transaction 4 January 2021
-------------------------- -------------------------------------------
f) Place of the transaction Outside a trading venue
-------------------------- -------------------------------------------
For further information, please contact:
e-therapeutics plc Tel: +44 (0) 1993 883 125
Ali Mortazavi, Executive Chairman www.etherapeutics.co.uk
Laura Roca-Alonso, Chief Business
Officer
Numis Securities Limited Tel: +44 (0) 207 260 1000
Freddie Barnfield/Duncan Monteith www.numis.com
(Nominated Adviser)
James Black (Corporate Broking)
About e-therapeutics plc
e-therapeutics plc is an Oxford, UK-based company with a
powerful computer-based approach to drug discovery, founded on its
industry-leading expertise in network biology to fully capture
disease complexity. The Company combines network science, machine
learning, artificial intelligence, statistics and access to big
data with expertise in drug discovery and development to transform
the search for new medicines and intervention strategies.
e-therapeutics has developed an in silico laboratory that
enables the rapid screening of millions of compounds and the
identification of small sub-sets that are enriched for highly
active hits. Its proprietary platform also has novel applications
in functional genomics, being able to analyse complex genetic
datasets, provide a deep understanding of pathological mechanisms
and distil actionable insights for the discovery of novel drugs,
biomarkers and diagnostics.
e-therapeutics has deployed and validated its disease-agnostic
drug discovery platform both in house and with partners, including
Novo Nordisk, Galapagos NV and a US-based, top 5 pharmaceutical
company.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHFLFFRLTISIIL
(END) Dow Jones Newswires
January 04, 2021 11:31 ET (16:31 GMT)
E-therapeutics (LSE:ETX)
Historical Stock Chart
From Apr 2024 to May 2024
E-therapeutics (LSE:ETX)
Historical Stock Chart
From May 2023 to May 2024